With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Keeping with its track record of launching a range of biosimilars before its peers, India's Dr. Reddy's Laboratories Ltd. is set to launch its indigenously developed pegylated filgrastim - a version of Amgen Inc.'s blockbuster Neulasta used to boost white blood cells in patients undergoing chemotherapy. Neulasta had global sales of around $3.6 billion last year, said an expert in the biotechnology industry
You may also be interested in...
Apotex Biosimilar Goes To FDA, But May Enter Crowded Market
Pegfilgrastim product, a collaboration with the Indian firm Intas, may have to compete with multiple filgrastim products, along with its reference biologic, Amgen’s Neulasta.
Apotex Biosimilar Goes To FDA, But May Enter Crowded Market
Pegfilgrastim product, a collaboration with the Indian firm Intas, may have to compete with multiple filgrastim products, along with its reference biologic, Amgen’s Neulasta.
Zydus Cadila Leading Global Race For Humira Biosimilar?
India’s Zydus Cadila stands a bright chance of leading the heated global chase to launch a biosimilar version of adalimumab, AbbVie’s blockbuster Humira, which is also the top-selling drug in the world notching close to $11 billion last year.